We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1076
United Therapeutics
UTHR
$22.1B
| $1.22M | ﹤0.01% |
4,246
-470
| -10% | -$140K |
|
1077
Fortive
FTV
$18B
| $1.21M | ﹤0.01% |
23,239
-28,389
| -55% | -$1.49M |
|
1078
Protolabs
PRLB
$1.91B
| $1.21M | ﹤0.01% |
30,233
-5
| -0% | -$186 |
|
|
SEMR
1079
DELISTED
Semrush
SEMR
| $1.2M | ﹤0.01% |
133,024
-180,210
| -58% | -$1.74M |
|
1080
BJs Wholesale Club
BJ
$11.4B
| $1.2M | ﹤0.01% |
11,107
-194
| -2% | -$22.1K |
|
1081
American Public Education
APEI
$842M
| $1.2M | ﹤0.01% |
39,286
-78
| -0.2% | -$2.06K |
|
1082
American Vanguard Corp
AVD
$64.6M
| $1.19M | ﹤0.01% |
303,179
+238,822
| +371% | +$996K |
|
1083
Albemarle Corp Depositary Shares
ALB.PRA
$2.57B
| $1.19M | ﹤0.01% |
37,000
| – | – |
|
1084
8x8 Inc
EGHT
$287M
| $1.19M | ﹤0.01% |
605,603
-19,174
| -3% | -$33.9K |
|
1085
PTC Therapeutics
PTCT
$5.85B
| $1.19M | ﹤0.01% |
24,284
-51,061
| -68% | -$2.42M |
|
1086
NeoGenomics
NEO
$2.32B
| $1.18M | ﹤0.01% |
161,683
+255
| +0.2% | +$2.06K |
|
1087
Semtech
SMTC
$12.2B
| $1.18M | ﹤0.01% |
26,117
-163,628
| -86% | -$5.82M |
|
1088
EVgo
EVGO
$196M
| $1.18M | ﹤0.01% |
322,678
+855
| +0.3% | +$2.93K |
|
|
HONE
1089
DELISTED
HarborOne Bancorp
HONE
| $1.17M | ﹤0.01% |
99,901
+314
| +0.3% | +$3.43K |
|
1090
Roper Technologies
ROP
$42.2B
| $1.16M | ﹤0.01% |
2,050
-2,550
| -55% | -$1.44M |
|
1091
Neurocrine Biosciences
NBIX
$15.7B
| $1.16M | ﹤0.01% |
9,239
-202
| -2% | -$23.2K |
|
1092
Simulations Plus
SLP
$372M
| $1.16M | ﹤0.01% |
66,459
+55,259
| +493% | +$1.55M |
|
1093
Encompass Health
EHC
$11.9B
| $1.15M | ﹤0.01% |
9,410
-130
| -1% | -$14.8K |
|
1094
ITT
ITT
$18.1B
| $1.15M | ﹤0.01% |
7,347
-361
| -5% | -$51.4K |
|
1095
BancFirst
BANF
$3.71B
| $1.15M | ﹤0.01% |
9,312
+37
| +0.4% | +$4.4K |
|
1096
D.R. Horton
DHI
$41.2B
| $1.15M | ﹤0.01% |
8,921
-6,696
| -43% | -$825K |
|
1097
First Horizon
FHN
$11.7B
| $1.15M | ﹤0.01% |
54,125
+4,507
| +9% | +$85.9K |
|
1098
Signet Jewelers
SIG
$3.21B
| $1.14M | ﹤0.01% |
14,340
-597
| -4% | -$39.7K |
|
1099
Phinia Inc
PHIN
$2.52B
| $1.14M | ﹤0.01% |
25,601
-43,210
| -63% | -$1.82M |
|
1100
Jones Lang LaSalle
JLL
$17.4B
| $1.14M | ﹤0.01% |
4,445
-6,777
| -60% | -$1.55M |
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.